Best Managed Healthcare Companies To Invest In Right Now

Linked here is a detailed quantitative analysis of Coca-Cola Company (KO). Below are some highlights from the above linked analysis:

Company Description: The Coca-Cola Company is the world's largest soft drink company, KO also has a sizable fruit juice business.

Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value (see page 2 of the linked PDF for a detailed description):

1. Avg. High Yield Price
2. 20-Year DCF Price
3. Avg. P/E Price
4. Graham Number

KO is trading at a premium to all four valuations above. The stock is trading at a 5.2% premium to its calculated fair value of $38.25. KO did not earn any Stars in this section.

Dividend Analytical Data: In this section there are three possible Stars and three key metrics (see page 2 of the linked PDF for a detailed description):

1. Free Cash Flow Payout
2. Debt To Total Capital
3. Key Metrics
4. Dividend Growth Rate
5. Years of Div. Growth
6. Rolling 4-yr Div. > 15%

Best European Companies To Buy For 2015: Catamaran Corp (CTRX)

Catamaran Corporation (Catamaran), formerly SXC Health Solutions Corp., incorporated on June 27, 2007, is a provider of pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefit management industry. The Company�� product offerings and solutions combine a range of applications and PBM services designed to assist its customers in reducing the cost and managing the complexity of their prescription drug programs. The Company�� customers include organizations in the pharmaceutical supply chain, such as pharmacy benefit managers, managed care organizations, self-insured employer groups, unions, third party health care plan administrators, and state and federal government entities. In January 2012, the Company completed its acquisition of HealthTran LLC (HealthTran). On July 2, 2012, the Company acquired Catalyst Health Solutions, Inc. On October 1, 2013, the Company acquired RESTAT, LLC.

The Company�� PBM services, which are marketed under the Catamaran PBM brand, include electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail pharmacy claims management, specialty pharmacy claims management, Medicare Part D services, benefit design consultation, preferred drug management programs, drug review and analysis, consulting services, data access, and reporting and information analysis. The Company's PBM services include owning and operating a network of mail and specialty pharmacies. In addition, the Company is a national provider of drug benefits to its customers under the federal government�� Medicare Part D program. The Company�� HCIT solutions include RxCLAIM, an on-line transaction processing system that provides instant adjudication of prescription drug claims, RxMAX, the Company�� rebate management system, RxTRACK, the Company�� data warehouse and analysis system, Zynchros, the Company�� suite of on-demand formulary management tools, the Company�� pharmacy management system! for retail, chain, institutional and mail-order pharmacies, as well as a number of other software products for customers in the pharmaceutical supply chain. The Company�� HCIT solutions are available on a license basis with on-going maintenance and support or on a transaction fee basis using an application service provider (ASP) model.

PBM Services

The Company�� informedRx offering is a suite of customizable PBM services that provide an alternative to traditional PBM offerings typically employed by health plans, government agencies and employers. The Company provides a range of pharmacy spend management solutions and information technology capabilities to managed care organizations, self-insured employer groups, unions, third party health care plan administrators, and state and federal government entities. Formulary Administration provides support for customers��existing formularies and preferred drug lists or collaborate to create models supported by formulary predictive modeling and impact analysis. Pharmacist, physician and member-focused intervention protocols provide controls to drive generics, preferred drug products and appropriate use. Formularies are administered based on specific plan designs, or by enabling customers with the tools to maintain their own custom formularies online.

The Company specializes in applying data-driven insights to help customers understand the medical risk drivers within their population and take a strategic approach to plan design. The Company provides benefit design configuration and support to customers, in accordance with mutually developed processes. Benefit designs can be modified online, in real time, by the Company or by the customer�� staff. Pharmacy Network Management provides a range of retail network options, including supporting existing networks or assisting customers in developing networks that meet specific geographic access requirements, desired price discounts, or other service requirements. A national! retail n! etwork, which consists of pharmacies in all 50 states and in Puerto Rico, Guam and the Virgin Islands, provides access to the Company�� customers.

Drug Utilization Review (DUR) is pre-dispensing DUR edit checks are performed on an online, real-time basis between mail and retail pharmacies to encourage appropriate drug utilization, enhance member outcomes, and reduce drug costs. All prescriptions are checked for member eligibility and plan design features and are then compared against previous histories of prescriptions filled by the same pharmacy, by other participating retail network pharmacies and by the mail service pharmacy. Clinical Services and Consulting provides consultative and technical expertise to augment, develop, deploy, and support any additional clinical programs. Reporting and Information Analysis Solutions provides two levels of reporting: a reporting package (which includes a menu of reports), and an online analytical decision support tool, RxTRACK. The Company offers mail and specialty services to its PBM members, as well as other members of its pharmacy network. suite of Web-based services that enables customers to interact with the claims processing system using a standardized protocol in a secure environment. A member Website, RxPORTAL, invites members to learn more about their prescription benefit programs, medication histories, drug information and related industry news. RxPROVIDER PORTAL is a Web-based interface that allows pharmacists and physicians to obtain information from RxCLAIM on a member's plan to assist in providing more cost effective prescription medications.

Healthcare IT

The Company's HCIT offerings deliver applications on a license, ASP, or fee-for-service basis to customers who administer and manage pharmacy benefits. HCIT products and services serve a diversified group of payor customers that include health plans, federal, state and provincial government programs, pharmacy benefit managers, workers' compensation programs! , and lon! g-term and/or chronic care facility operators. In addition, SXC's technology serves as the engine for the Company's service PBM solutions.

Technology Products and Services

RxCLAIM is an on-line transaction processing system designed to provide instant on-line adjudication of third-party prescription drug claims at the point of service, including claims management, as well as payment and billing support and real-time functionality for updating benefit, price, member, provider and drug details. RxCLAIM is designed to provide the Company�� customers control by facilitating the real-time processing of pharmacy claims and payments against eligibility, plan benefits, formularies, price, drug utilization review, prior authorization, and rebates in addition to many other features.

Other products

Integrail Pathfinder PRO is a software application that enables a array of users to understand the impact of healthcare resource allocation and medical decision-making through the incorporation of risk prediction and episode profiling technologies. The application offers users an intuitive system for integrating disparate data sources to pinpoint variations in resource utilization and care. IntegrailRx features the ability to measure and predict both pharmacy and total risk using pharmacy claims. RxBUILDER is a Web-based interface for formulary creation and maintenance utilizing a Medi-Span based product file. RxPORTAL allows customers to interact with the patient's formulary and drug history in a secure environment allowing patients and health plans to access industry tools and up to date information. RxAUTH is a prior authorization (PA) management solution, which offers automating the PA process from end-to-end. RxAUTH is also available in a Web-based application. RxMAX is a rebate management system that is designed to assist health plans in managing their relationships with pharmaceutical manufacturers through contract management, record keeping, calculating market share! , and cre! ating billing details and summaries. Zynchros provides a suite of on-demand formulary management tools to help payors effectively manage their formulary programs, and to maintain Medicare Part D compliance in their programs. Enhanced Coordination of Benefits integrates external data sources with unique algorithms and eligibility data to identify beneficiaries with other coverage. This enables accurate identification of third party liability in real-time prior to the claim being paid.

Medicare Part D

The Company has offered an array of services to the Medicare marketplace, all compliant with Centers for Medicare and Medicaid Services (CMS) regulations. As a full-service PBM and a National Prescription Drug Plan, the Company supports a variety of Medicare Part D Plan Sponsors. The Company provides prescription benefit management support for Medicare Advantage Prescription Drug plans (MAPDs) and prescription drug plans (PDPs), including implementation of specific Medicare Part D plan designs, creation and maintenance of Medicare Part D formularies (including CMS submission), CMS reporting requirements and consultative, proactive account management.

The Company competes with Express Scripts, Inc., CVS/Caremark Corporation and OptumRx.

Advisors' Opinion:

• [By Brian Pacampara]

  What: Shares of health care IT services specialist Catamaran (NASDAQ: CTRX  ) sank 10% today after the company's quarterly results and outlook disappointed Wall Street. �

Best Managed Healthcare Companies To Invest In Right Now: Rock Energy Inc (RENFF.PK)

Rock Energy Inc. (Rock) is an energy company engaged in the exploration for and development and production of crude oil and natural gas in Western Canada. Rock owns 35,915 (35,881 net) acres of land in the Plains area of east central Alberta and west central Saskatchewan. Rock owns 6,280 (5,960 net) acres of land in the Onward area of south west Saskatchewan, which consists primarily of two Lloydminster heavy oil pools. As of December 31, 2011, the Mantario area consisted of 4,480 (4,480 net) acres of land. Its Bigstone area, which is within the Greater Kaybob region includes Rock�� Saxon, Tony Creek and Waskahigan properties. As of December 31, 2011, Rock owned 101,278 (58,992 net) acres of land in the Elmworth area of Alberta, with two dimensions (2D) and three dimensions (3D) seismic coverage. The property included 38 (12.77 net) producing natural gas wells. During the first quarter of 2012, Rock acquired an additional 5,748 (5,748 net) acres of land. Advisors' Opinion:

• [By Value Digger]

  Same thing happened with Rock Energy (RENFF.PK), when I recommended it at $1 about three months ago. My article is here.

  Rock Energy is at $1.3 today, and its annual report confirmed my bullish call. I have been alone in that bullish call once again.

Best Managed Healthcare Companies To Invest In Right Now: Tetraphase Pharmaceuticals Inc (TTPH)

Tetraphase Pharmaceuticals, Inc., incorporated on July 7, 2006, is a clinical stage biopharmaceutical company. The Company�� product candidate, eravacycline, is a fully synthetic tetracycline derivative that the Company are developing as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections. The Company�� frequently used products, such as Zyvox and Cubicin, are limited to Gram-positive bacteria and thus are rarely used as a first-line empiric monotherapy if broad bacterial coverage is required. During the year ended December 31, 2012, completed a Phase 2 clinical trial of eravacycline with intravenous administration for the treatment of patients with complicated intra-abdominal infections, or cIAI, and are finalizing its pivotal Phase 3 program for eravacycline. In 2012, in vitro experiments, eravacycline has demonstrated the ability to cover a variety of multi-drug resistant Gram-negative, Gram-positive, anaerobic and atypical bacteria, including multi-drug resistant Klebsiella pneumoniae, the species of Gram-negative bacteria that killed seven patients at the Clinical Center of the National Institutes of Health.

Gram-positive bacteria that have developed resistance to existing drugs include: Streptococcus pneumoniae that cause pneumonia, ear infections, bloodstream infections and meningitis; Staphylococcus aureus that cause skin, bone, lung and bloodstream infections, and Enterococci that are responsible for infections transmitted in healthcare settings. Gram-negative bacteria that have developed resistance to existing drugs include: Escherichia coli that cause urinary tract, skin and bloodstream infections; Salmonella and Escherichia coli that cause foodborne infections, and Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella spp.

In addition, other antibiotics that have been used as first-line empiric monothe! rapies, such as Levaquin, piperacillin/tazobactam, which is marketed by Pfizer as Zosyn, carbapenems, such as Merrem, and imipenem/cilastatin, which is marketed by Merck as Primaxin, have seen their utility as first-line empiric monotherapies diminished as the number of bacterial strains resistant to these therapies has increased. In addition to developing an intravenous formulation of eravacycline, the Company is also developing an oral formulation. A number of previous tetracyclines have been available in both intravenous and oral dosage forms. Infections that are resistant to existing oral drugs are increasingly common, and the Company believe that an intravenous-to-oral step-down therapy in which patients are started on the intravenous formulation of eravacycline and then stepped down to an oral formulation of eravacycline could reduce the length of a patient�� hospital stay or help avoid hospital admission altogether, lowering the overall cost of care for these patients.

Advisors' Opinion:

• [By Roberto Pedone]

  Another under-$10 biopharmaceutical player that's starting to trend within range of triggering a near-term breakout trade is Tetraphase Pharmaceuticals (TTPH), which using its proprietary chemistry technology creates novel antibiotics for serious and life-threatening multi-drug resistant infections. This stock is off to a strong start in 2013, with shares up 19.4%.

  If you take a look at the chart for Tetraphase Pharmaceuticals, you'll notice that this stock has just started to trend back above its 50-day moving average of $7.76 a share with decent upside volume flows. That move is quickly pushing shares of TTPH within range of breaking out above some key near-term overhead resistance levels that have acted as a ceiling for the stock for the last three months.

  Market players should now look for long-biased trades in TTPH if it manages to break out above some near-term overhead resistance levels at $8.30 to $8.40 a share and then once it takes out more resistance at $8.50 to $9 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 62,234 shares. If that breakout triggers soon, then TTPH will set up to re-test or possibly take out its all-time high at $9.66 a share. Any high-volume move above that level will then push TTPH into new all-time high territory, which is bullish technical price action. Some possible upside targets off that move are $12 to $13 a share.

  Traders can look to buy TTPH off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $7.76 a share, or below more key near-term support levels at $7.37 to $7.02 a share. One can also buy TTPH off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Best Managed Healthcare Companies To Invest In Right Now: BG Medicine Inc.(BGMD)

BG Medicine, Inc., a life sciences company, engages in the discovery, development, and commercialization of diagnostic tests based on biomarkers in the United States. Its product pipeline includes BGM Galectin-3, a diagnostic test for heart failure that measures galectin-3 levels in blood plasma or serum; AMIPredict, a multivariate biomarker blood-based test for atherothrombotic cardiovascular disease; and LipidDx, a blood-based protein assay for the management of patients with lipid disorders. The company also offers TNF alpha blockers comprising Enbrel, Remicade and Humira, which are treatments indicated for autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn?s disease. It has strategic collaborations and initiatives with pharmaceutical companies and other healthcare organizations, including Abbott Laboratories; ACS Biomarker B.V.; Humana Inc.; Merck & Co., Inc.; and Laboratory Corporation of America. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

Advisors' Opinion:

• [By Roberto Pedone]

  Another stock that's starting to move within range of triggering a big breakout trade is BG Medicine (BGMD), which develops and commercializes novel cardiovascular diagnostic tests to address unmet medical needs in the U.S. This stock has been pushed lower by the sellers over the last three months, with shares down sharply by 20%.

  If you take a glance at the chart for BG Medicine, you'll notice that this stock has been uptrending a bit for the last month, with shares moving higher from its low of 90 cents per share to its recent high of $1.12 a share. During that uptrend, shares of BGMD have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of BGMD within range of triggering a big breakout trade above some key near-term overhead resistance levels.

  Traders should now look for long-biased trades in BGMD if it manages to break out above some near-term overhead resistance levels at $1.08 to $1.12 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.56 million shares. If that breakout gets started soon, then BGMD will set up to re-fill some of its previous gap-down-day zone from May that started near $1.30 a share. Any high-volume move above $1.30 will then give BGMD a chance to tag its next major overhead resistance levels at $1.50 to around $1.70 a share.

  Traders can look to buy BGMD off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at 96 cents to 90 cents per share. One can also buy BGMD off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By James E. Brumley]

  What do BG Medicine, Inc. (NASDAQ:BGMD) and Pentair, Ltd. (NYSE:PNR) have in common? Most investors would say absolutely nothing. BGMD is a small cap medical diagnostics company, while PNR is a large cap industrial equipment manufacturer. Those are worlds that simply never collide. The directions each stock has been traveling in over the past few months have even been polar opposites.

Best Managed Healthcare Companies To Invest In Right Now: Roadrunner Transportation Systems Inc (RRTS)

Roadrunner Transportation Systems, Inc. operates as a non-asset based transportation and logistics service company. It provides a suite of solutions, including customized and expedited less-than-truckload, truckload brokerage, transportation management solutions, intermodal solutions, and domestic and international air services. The company is headquartered in Cudahy, Wisconsin.

Advisors' Opinion:

• [By Seth Jayson]

  Roadrunner Transportation Systems (NYSE: RRTS  ) reported earnings on May 1. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q1), Roadrunner Transportation Systems beat slightly on revenues and beat expectations on earnings per share.

• [By Rich Smith]

  This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines feature a pair of downgrades for lululemon athletica (NASDAQ: LULU  ) and Roadrunner Transportation (NYSE: RRTS  ) . But the news isn't all bad, so before we get into that news, let's find out first why one analyst thinks...

• [By Seth Jayson]

  Margins matter. The more Roadrunner Transportation Systems (NYSE: RRTS  ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong Roadrunner Transportation Systems's competitive position could be.

Best Managed Healthcare Companies To Invest In Right Now: BRE Properties Inc (BRE)

BRE Properties, Inc. (BRE), incorporated in 1970, is a self-administered equity real estate investment trust (REIT) focused on the development, acquisition and management of multifamily apartment communities primarily located in the metropolitan markets within the State of California, and the Seattle, Washington region. BRE also owns and operates communities in the Phoenix, Arizona and in the Denver, Colorado metropolitan markets. As of December 31, 2011, its multifamily portfolio had real estate assets, which included 76 wholly or majority owned stabilized multifamily communities, aggregating 21,336 units in California, Washington and Arizona; 11 stabilized multifamily communities owned through joint ventures comprised of 3,592 apartment units; and seven apartment communities in various stages of construction and development. In October 2013, the Company acquired Jefferson at Hollywood.

During the year ended December 31, 2011, BRE acquired three communities totaling 652 units: Lafayette Highlands, with 150 units, located in Lafayette, California; The Landing at Jack London Square, with 282 units, located in Oakland, California, and The Vistas of West Hills, with 220 units, located in Valencia, California. In addition to the communities, the Company acquired two parcels of land for future development in San Francisco, California�� Mission Bay district, and it purchased a 4.4 acre site contiguous to its existing Park Viridian operating community and its existing second phase land site in Anaheim, California. As of December 31, 2011, BRE had seven sites under development or construction.

During 2011, the Company sold two communities totaling 634 units: Galleria at Towngate, with 268 units located in Moreno Valley, California; and Windrush Village, a 366 unit property located in Colton, California. The two properties sold were located in the eastern half of the Inland Empire. In addition, during 2011, two joint venture assets were sold; The Landing at Bear Creek, a 224 unit j! oint venture community, located in Lakewood, Colorado; and The Pinnacle at Hunters Glen, a 264 unit joint venture community located in Thornton, Colorado.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  BRE Properties (NYSE: BRE) was also up, gaining 11.79 percent to $59.66 after Bloomberg reported that the company is working with Wells Fargo on a possible sale.

• [By Jayson Derrick]

  Shares of BRE Properties Inc. (NYSE: BRE) jumped to new 52 week highs of $61.50, immediately following a Bloomberg report that the company is working with investment bankers at Wells Fargo (NYSE: WFC) for a possible sale of the company.